Description: Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026.

Description: Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians detect cancer recurrence earlier than traditional imaging. The expanded offerings include Labcorp Plasma Detect ID, a whole exome sequence-guided, personalized panel for patients with stage I–III breast cancer or stage I–IIIA non-small cell lung cancer, and the nationwide availability of Lab

Description: Recent trading in Labcorp Holdings (LH) has drawn attention after the stock showed a 10.5% decline over the past 3 months, prompting investors to reassess its current valuation and long term return profile. See our latest analysis for Labcorp Holdings. The recent 10.5% 3 month share price decline sits against a relatively steady year to date share price return of around flat, while the 1 year total shareholder return of 8.15% suggests momentum has cooled rather than collapsed. If Labcorp’s...

Description: Consumer Report Details Low Testosterone Treatment Costs, LabCorp and Quest Lab Testing, Licensed Provider Access, and What Men Need to Know Before Starting Online TRTWILMINGTON, DE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Testosterone replacement therapy requires evaluation by a licensed healthcare provider. If you access services through links in this article, a commission may be earned at no additional cost to yo

Description: Here’s what you need to know about Labcorp Holdings prior to its Q4 earnings release.

Description: The move adds Labcorp’s US biocompatibility, analytical testing, and preclinical research services to Namsa’s operations.

Description: SAN JOSE, Calif., January 08, 2026--Today, Visby Medical announced two new relationships that will expand national access to the Visby Women’s Sexual Health Test, the first, at-home, FDA-authorized PCR test for sexually transmitted infections (STIs) available to consumers, enabling immediate access to Visby’s integrated "Test-to-Treat" ecosystem. The palm-sized device delivers confidential results in just 30 minutes, providing women with a rapid response for chlamydia, gonorrhea, and trichomonia

Description: NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide.

Description: SAN DIEGO, January 06, 2026--PracticeQ and Fullscript partner to simplify lab ordering and results management, helping providers deliver faster, more connected care.

Description: LH's growth bets in specialty testing and acquisitions support its outlook, but macro pressures and currency headwinds remain key risks.

Description: Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, at 4:30 p.m. PT.

Description: Labcorp's strategic partnerships, specialty test growth and more attractive valuation tilt the balance as it emerges stronger than Hologic right now.

Description: DHR sees Biotechnology core revenues rise 6.5% in Q3 2025, fueled by bioprocessing demand, with approximately 5% growth expected in Q4.

Description: Labcorp Holdings recently reported better-than-expected Q3 2025 adjusted EPS of $4.18 but cut its contract research unit’s annual and full-year revenue growth forecasts due to a prolonged funding crunch and delays in early-stage clinical study starts. At the same time, the company is seeing board-level change with the planned year-end 2025 retirement of long-standing director Dr. D. Gary Gilliland, while continuing to invest in precision oncology through backing Cofactor Genomics to expand...

Description: ST. LOUIS, December 15, 2025--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures. The financing is intended to accelerate Cofactor’s nationwide expansion and broaden patient access to its immunotherapy-response diagnostics.

Description: Investors need to pay close attention to LH stock based on the movements in the options market lately.

Description: Despite Labcorp Holdings’ underperformance relative to its industry peers, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Description: Shares of CYH decline 7%. Heavy debt, soft patient volumes and ongoing investor concerns keep pressure on the hospital operator.

Description: Labcorp Holdings (LH) has quietly outperformed many healthcare peers this year, and the stock’s recent move has investors asking whether steady earnings growth and diagnostics demand can keep driving gains from here. See our latest analysis for Labcorp Holdings. That steady backdrop has helped Labcorp’s share price grind higher to around $259.94 this year, with a solid year to date share price return and an 11.4 percent one year total shareholder return suggesting momentum is constructive...

Description: If you are wondering whether Labcorp Holdings is still attractively priced today, or if most of the upside has already been captured, you are in the right place to explore what the market might be overlooking. The stock has eased off slightly in the last week, down 2.9%. It is still up 2.9% over the last month, 13.9% year to date and 11.4% over the past year, with longer term gains of 38.0% over three years and 55.2% over five years that hint at a steadily compounding story. Recent headlines...

Description: The deal, first announced in July, includes outreach laboratory services in 13 states. CHS will continue to operate inpatient and emergency department labs.

Description: Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: FRANKLIN, Tenn. & BURLINGTON, N.C., December 02, 2025--Community Health Systems, Inc. (the "Company") (NYSE: CYH) announced today that its subsidiary, CHS/Community Health Systems, Inc. (CHS), has completed the sale of select assets of the ambulatory outreach laboratory services of CHS-affiliated health systems in 13 states, including certain patient service centers and in-office phlebotomy locations, to Labcorp (NYSE: LH) for approximately $194 million cash, before certain transaction expenses.

Description: Labcorp expands in specialty testing and ramps up acquisitions, but macro pressures and currency headwinds complicate its growth outlook.

Description: CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Labcorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025.

Description: Labcorp Holdings (LH) is drawing attention after its Plasma Detect assay was featured in two respected medical journals. The company’s digital pathology joint initiative with Lunit also made headlines at recent oncology conferences. See our latest analysis for Labcorp Holdings. Momentum has been building for Labcorp Holdings over 2025, with investor optimism fueled by advances in diagnostics and AI partnerships. The stock’s strong 1-year total shareholder return of 12.1% reflects both robust...

Description: Labcorp shares edge higher as new studies spotlight Plasma Detect's role in tracking MRD and improving post-surgery cancer detection.

Description: While Labcorp Holdings has underperformed the S&P 500 Index slightly over the past year, its YTD strength stands out. Analysts remain firmly bullish on the stock's growth potential.

Description: Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care.

Description: Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced Labcorp Plasma Detect, a tumor-informed, blood-based assay used to detect molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two recent peer-reviewed publications – Nature Medicine and Clinical Cancer Research.

Description: Lunit and Labcorp recently announced a collaboration to advance innovation in digital pathology and artificial intelligence for oncology research, leveraging Labcorp's clinical and pathology expertise alongside Lunit's AI algorithms. This partnership has already yielded research results presented at key scientific conferences, highlighting the potential of AI-driven spatial profiling to identify immune phenotypes in non-small cell lung cancer and guide precision immuno-oncology...

Description: Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care.

Description: The takeover extends a string of deals that have consolidated the outreach lab services market.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: Labcorp Holdings Inc. ( NYSE:LH ) has announced that it will pay a dividend of $0.72 per share on the 11th of December...

Description: Even though Labcorp Holdings Inc. ( NYSE:LH ) posted strong earnings, investors appeared to be underwhelmed. We did...

Description: Labcorp’s third quarter results met Wall Street’s revenue expectations, but the market responded negatively, reflecting investor concerns about profitability and future growth levers. Management attributed the quarter’s performance to robust organic growth in its Diagnostics segment—especially through increased demand for specialty and genetic testing platforms like Invitae. CEO Adam Schechter explained that "margin for the quarter improved 100 basis points, driven by Diagnostics," and highlight

Description: OLATHE, Kan., November 03, 2025--KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. Their addition marks a significant milestone in KCAS Bio’s continued growth and strategic evolution in the global life sciences industry. KCAS Bio is headquartered in the Kansas City, Kansas metropolitan area with operating sites i

Description: OPKO Health recently reported third-quarter earnings with revenue of US$151.67 million and net income of US$21.63 million, surpassing analyst expectations, and announced a collaboration with Regeneron Pharmaceuticals potentially valued at over US$1 billion. The company also finalized the US$225 million sale of its BioReference Health oncology assets to Labcorp and received FDA approval for broader use of its 4Kscore® Test, marking significant changes in its business focus and regulatory...

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

Description: Labcorp Holdings Inc (LH) reports a robust 9% revenue increase and a 19% rise in adjusted EPS, while navigating challenges in early development and currency impacts.

Description: Labcorp Holdings (LH) posted a net profit margin of 6.2% for the period, up from 3.4% a year ago, as earnings surged 96.4% year-over-year. This is well above the company's five-year average despite a longer-term earnings decline of 30.6% per year. Shares sit at $248.14, notably below the estimated fair value of $557.86. The current price-to-earnings ratio of 24.1x is higher than peer and industry averages. Investors are eyeing a potential turnaround as earnings are forecast to grow 14% per...

Description: Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its non-GAAP profit of $4.18 per share was 1% above analysts’ consensus estimates.

Description: Shares of healthcare diagnostics company Labcorp Holdings (NYSE:LH) fell 3.8% in the morning session after the company's third-quarter results, while beating headline estimates, revealed a miss on a key profitability metric and included guidance that failed to impress investors. The healthcare diagnostics company reported revenue of $3.56 billion, in line with Wall Street expectations, and an adjusted profit of $4.18 per share, which was 1% above consensus. However, investors looked past the top

Description: Labcorp's Q3 earnings beat forecasts and margins improve, but a trimmed 2025 sales outlook sends shares down.

Description: Margin for the quarter improved 100 basis points, driven by Diagnostics. Adjusted EPS grew 19%, and we generated strong free cash flow of $281 million. Moving to our business segments, Diagnostics revenue increased 8.5%, primarily due to strong organic growth of 6%.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: While the top- and bottom-line numbers for Labcorp (LH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its non-GAAP profit of $4.18 per share was 1% above analysts’ consensus estimates.

Description: Labcorp (LH) delivered earnings and revenue surprises of +1.21% and -0.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Labcorp Holdings Inc. ( NYSE:LH ) will pay a dividend of $0.72 on the 11th of December. This payment means the dividend...

Description: The Burlington, North Carolina-based company said it had profit of $3.12 per share. Earnings, adjusted for one-time gains and costs, came to $4.18 per share. The results surpassed Wall Street expectations.

Description: Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2025 and updated full-year guidance.

Description: Healthcare diagnostics company Labcorp Holdings (NYSE:LH) will be reporting results this Tuesday before market open. Here’s what to look for.

Description: Labcorp announced it will begin offering the Elecsys pTau181 blood test nationwide by early 2026, making available the only FDA-cleared blood test in the U.S. to aid in the initial assessment for Alzheimer’s disease and cognitive decline in primary-care settings. This marks a significant step forward in expanding access to less invasive neurological diagnostics, helping streamline the testing process for an estimated 7.2 million Americans living with Alzheimer’s disease. We’ll now explore...

Description: Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting. Developed by Roche Diagnostics, Labcorp plans to make the test available nationwide by early 2026.

Description: We came across a bullish thesis on Quest Diagnostics Incorporated on Quality Value Investing’s Substack by David J. Waldron. In this article, we will summarize the bulls’ thesis on DGX. Quest Diagnostics Incorporated’s share was trading at $185.39 as of October 14th. DGX’s trailing and forward P/E were 21.67 and 17.12 respectively according to Yahoo Finance. Quest […]

Description: Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Opportunities in the global fertility test market include rising demand due to lifestyle changes, delayed pregnancies, and increasing infertility rates. Growing awareness and acceptance of fertility testing, alongside the prevalence of reproductive disorders, also drive market expansion across diverse demographics globally. Fertility Test Market Fertility Test Market Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "Fertility Test Market Size, Share & Trends Analysis Report by Test Type (Ovulation

Description: Labcorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Description: AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.

Description: LH vs. DHR: Which Stock Is the Better Value Option?

Description: CHICAGO, October 20, 2025--A streamlined digital experience improved lab order adherence, reduced no-shows, and enhanced operational efficiency at Providence.

Description: Labcorp Holdings (LH) shares inched up about 1% today, adding to their steady gains over the past month. With recent momentum continuing, investors are considering what factors could drive further moves in the healthcare giant’s stock. See our latest analysis for Labcorp Holdings. Labcorp Holdings has delivered a robust run this year, with the share price rallying more than 25% year to date and momentum accelerating over the past quarter. Investors have seen an impressive 34% total...

Description: While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".